128 related articles for article (PubMed ID: 7522110)
21. High-dose chemotherapy and autologous stem cell support followed by posttransplantation doxorubicin as initial therapy for metastatic breast cancer.
deMagalhaes-Silverman M; Bloom E; Lembersky B; Lister J; Pincus S; Rybka W; Voloshin M; Wilson J; Ball E
Clin Cancer Res; 1997 Feb; 3(2):193-7. PubMed ID: 9815672
[TBL] [Abstract][Full Text] [Related]
22. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
[TBL] [Abstract][Full Text] [Related]
23. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF.
Hohaus S; Goldschmidt H; Ehrhardt R; Haas R
Exp Hematol; 1993 Apr; 21(4):508-14. PubMed ID: 7681782
[TBL] [Abstract][Full Text] [Related]
24. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
Haas R; Moos M; Möhle R; Döhner H; Witt B; Goldschmidt H; Murea S; Flentje M; Wannenmacher M; Hunstein W
Bone Marrow Transplant; 1996 Feb; 17(2):149-55. PubMed ID: 8640159
[TBL] [Abstract][Full Text] [Related]
25. Tandem transplants in solid tumors: marrow versus peripheral stem cell transplant: peripheral blood cells as now practiced are not the whole answer.
Spitzer G; Dunphy FR; Petruska PJ; Velasquez WS; Adkins DR
J Hematother; 1993; 2(3):363-5. PubMed ID: 7921997
[TBL] [Abstract][Full Text] [Related]
26. Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
Prince HM; Rischin D; Toner GC; Seymour JF; Blakey D; Gates P; Eerhard S; Chapple P; Quinn M; Brettell M; Juneja S; Wolf M; Januszewicz EH; Richardson G; Scarlett J; Briggs P
Bone Marrow Transplant; 2000 Nov; 26(9):955-61. PubMed ID: 11100274
[TBL] [Abstract][Full Text] [Related]
27. Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of breast cancer: a pilot trial.
Deisseroth AB; Holmes F; Hortobagyi G; Champlin R
Hum Gene Ther; 1996 Feb; 7(3):401-16. PubMed ID: 8835224
[No Abstract] [Full Text] [Related]
28. Peripheral blood progenitors mobilised by G-CSF (filgrastim) and reinfused as unprocessed autologous whole blood shorten the pancytopenic period following high-dose melphalan in multiple myeloma.
Ossenkoppele GJ; Jonkhoff AR; Huijgens PC; Nauta JJ; van der Hem KG; Dräger AM; Langenhuijsen MM
Bone Marrow Transplant; 1994 Jan; 13(1):37-41. PubMed ID: 7517255
[TBL] [Abstract][Full Text] [Related]
29. Autologous graft-versus-host disease induction in advanced breast cancer: role of peripheral blood progenitor cells.
van der Wall E; Horn T; Bright E; Passos-Coehlo JL; Bond S; Clarke B; Altomonte V; McIntyre K; Vogelsang G; Noga SJ; Davis JM; Thomassen J; Ohly KV; Lee SM; Fetting J; Armstrong DK; Davidson NE; Hess AD; Kennedy MJ
Br J Cancer; 2000 Dec; 83(11):1405-11. PubMed ID: 11076645
[TBL] [Abstract][Full Text] [Related]
30. Autologous platelet collection and storage to support thrombocytopenia in patients undergoing high-dose chemotherapy and circulating progenitor cell transplantation for high-risk breast cancer.
Torretta L; Perotti C; Pedrazzoli P; Dornini G; Viarengo G; Livraghi A; Noris P; Da Prada GA; Balduini CL; della Cuna GR; Salvaneschi L
Vox Sang; 1998; 75(3):224-9. PubMed ID: 9852411
[TBL] [Abstract][Full Text] [Related]
31. Maturation of mobilized peripheral blood progenitor cells: preclinical and phase I clinical studies.
Chang Q; Hanks S; Akard L; Thompson J; Harvey K; English D; Jansen J
J Hematother; 1995 Aug; 4(4):289-97. PubMed ID: 7489143
[TBL] [Abstract][Full Text] [Related]
32. [High-dosage chemotherapy and the autologous transplantation of peripheral hematopoietic progenitor cells in breast cancer: the initial results, analysis of toxicity and the necessary support means].
Sola Rocabert C; Mesía R; Mendoza L; Tabernero JM; Amill B; Maroto P; Bellet M; Ojeda B; Alonso MC; Verger G
Med Clin (Barc); 1995 Oct; 105(11):407-11. PubMed ID: 7475451
[TBL] [Abstract][Full Text] [Related]
33. Peripheral blood progenitor cell transplantation: a single centre experience comparing two mobilisation regimens in 67 patients.
Mahendra P; Johnson D; Scott MA; Jestice HK; Hood IM; Ager S; Bass G; Barker P; Boraks PA; Bloxham DM; Baglin TP; Marcus RE
Bone Marrow Transplant; 1996 Apr; 17(4):503-7. PubMed ID: 8722346
[TBL] [Abstract][Full Text] [Related]
34. Peripheral blood progenitor cell (PBPC) transplantation with a single apheresis in various malignancies.
Efremidis AP; Koumakis G; Filis J; Moraki M; Vassilomanolakis M; Barbounis V; Hatzichristou H; Papanastasiou K; Stamatellou M
Bone Marrow Transplant; 1996 Apr; 17(4):673-4. PubMed ID: 8722374
[No Abstract] [Full Text] [Related]
35. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer.
Bitran JD; Samuels B; Klein L; Hanauer S; Johnson L; Martinec J; Harris E; Kempler J; White W
Bone Marrow Transplant; 1996 Feb; 17(2):157-62. PubMed ID: 8640160
[TBL] [Abstract][Full Text] [Related]
36. Large volume leukapheresis following peripheral blood stem cell mobilization by cyclophosphamide and granulocyte-macrophage colony stimulating factor.
Safran H; Caguioa P; Tansan S
Prog Clin Biol Res; 1994; 389():639-42. PubMed ID: 7700930
[No Abstract] [Full Text] [Related]
37. Intensive cyclic chemotherapy and transplantation of autologous peripheral blood progenitor cells (PBPC) or whole blood in high-risk breast cancer - follow up at 10 years.
Cinek P; Filip S; Vanasek J; Mericka P; Blaha M; Zouhar M
Exp Oncol; 2007 Jun; 29(2):144-51. PubMed ID: 17704748
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer.
Schrama JG; Baars JW; Holtkamp MJ; Schornagel JH; Beijnen JH; Rodenhuis S
Bone Marrow Transplant; 2001 Jul; 28(2):173-80. PubMed ID: 11509935
[TBL] [Abstract][Full Text] [Related]
39. Quantitative assessment of colony growth and hematologic engraftment in patients undergoing high-dose chemotherapy and autologous bone marrow transplantation for breast cancer.
Meehan KR; Ericson SG; Tosteson TD; Mills LE
Prog Clin Biol Res; 1994; 389():497-503. PubMed ID: 7535459
[No Abstract] [Full Text] [Related]
40. High dose mitoxantrone with thiotepa, cyclophosphamide and autologous stem cell rescue for high risk stage II and stage III breast cancer. German GABG-4/EH-93-Study.
Zander AR; Krüger W; Kröger N; Damon L; Königmann M; Berdel WE; Gieseking F; Schäfer-Eckart K; Möbus V; Frickhofen N; Wandt H; Illiger HJ; Metzner B; Kolbe K; Wörmann B; Trümper L; Huber C; Hossfeld DK; Maass H; Jonat W
Bone Marrow Transplant; 1996 Sep; 18 Suppl 1():S24-5. PubMed ID: 8899165
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
